IBDEI2L2 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41226,2)
 ;;=^5002659
 ;;^UTILITY(U,$J,358.3,41227,0)
 ;;=E11.638^^152^2030^29
 ;;^UTILITY(U,$J,358.3,41227,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41227,1,3,0)
 ;;=3^DM Type 2 w/ Oth Oral Compl
 ;;^UTILITY(U,$J,358.3,41227,1,4,0)
 ;;=4^E11.638
 ;;^UTILITY(U,$J,358.3,41227,2)
 ;;=^5002660
 ;;^UTILITY(U,$J,358.3,41228,0)
 ;;=E11.641^^152^2030^20
 ;;^UTILITY(U,$J,358.3,41228,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41228,1,3,0)
 ;;=3^DM Type 2 w/ Hypoglycemia w/ Coma
 ;;^UTILITY(U,$J,358.3,41228,1,4,0)
 ;;=4^E11.641
 ;;^UTILITY(U,$J,358.3,41228,2)
 ;;=^5002661
 ;;^UTILITY(U,$J,358.3,41229,0)
 ;;=E11.649^^152^2030^21
 ;;^UTILITY(U,$J,358.3,41229,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41229,1,3,0)
 ;;=3^DM Type 2 w/ Hypoglycemia w/o Coma
 ;;^UTILITY(U,$J,358.3,41229,1,4,0)
 ;;=4^E11.649
 ;;^UTILITY(U,$J,358.3,41229,2)
 ;;=^5002662
 ;;^UTILITY(U,$J,358.3,41230,0)
 ;;=E11.65^^152^2030^17
 ;;^UTILITY(U,$J,358.3,41230,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41230,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,41230,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,41230,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,41231,0)
 ;;=E11.69^^152^2030^32
 ;;^UTILITY(U,$J,358.3,41231,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41231,1,3,0)
 ;;=3^DM Type 2 w/ Oth Spec Compl
 ;;^UTILITY(U,$J,358.3,41231,1,4,0)
 ;;=4^E11.69
 ;;^UTILITY(U,$J,358.3,41231,2)
 ;;=^5002664
 ;;^UTILITY(U,$J,358.3,41232,0)
 ;;=E11.8^^152^2030^34
 ;;^UTILITY(U,$J,358.3,41232,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41232,1,3,0)
 ;;=3^DM Type 2 w/ Unspec Compl
 ;;^UTILITY(U,$J,358.3,41232,1,4,0)
 ;;=4^E11.8
 ;;^UTILITY(U,$J,358.3,41232,2)
 ;;=^5002665
 ;;^UTILITY(U,$J,358.3,41233,0)
 ;;=E11.9^^152^2030^35
 ;;^UTILITY(U,$J,358.3,41233,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41233,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,41233,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,41233,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,41234,0)
 ;;=E11.29^^152^2030^27
 ;;^UTILITY(U,$J,358.3,41234,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41234,1,3,0)
 ;;=3^DM Type 2 w/ Oth Diab Kidney Compl
 ;;^UTILITY(U,$J,358.3,41234,1,4,0)
 ;;=4^E11.29
 ;;^UTILITY(U,$J,358.3,41234,2)
 ;;=^5002631
 ;;^UTILITY(U,$J,358.3,41235,0)
 ;;=E11.311^^152^2030^14
 ;;^UTILITY(U,$J,358.3,41235,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41235,1,3,0)
 ;;=3^DM Type 2 w/ Diab Rtnop w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,41235,1,4,0)
 ;;=4^E11.311
 ;;^UTILITY(U,$J,358.3,41235,2)
 ;;=E11.319^5002632
 ;;^UTILITY(U,$J,358.3,41236,0)
 ;;=E11.319^^152^2030^15
 ;;^UTILITY(U,$J,358.3,41236,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41236,1,3,0)
 ;;=3^DM Type 2 w/ Diab Rtnop w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,41236,1,4,0)
 ;;=4^E11.319
 ;;^UTILITY(U,$J,358.3,41236,2)
 ;;=^5002633
 ;;^UTILITY(U,$J,358.3,41237,0)
 ;;=E11.3211^^152^2030^22
 ;;^UTILITY(U,$J,358.3,41237,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41237,1,3,0)
 ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Rt Eye
 ;;^UTILITY(U,$J,358.3,41237,1,4,0)
 ;;=4^E11.3211
 ;;^UTILITY(U,$J,358.3,41237,2)
 ;;=^5138331
 ;;^UTILITY(U,$J,358.3,41238,0)
 ;;=E11.3212^^152^2030^23
 ;;^UTILITY(U,$J,358.3,41238,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41238,1,3,0)
 ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Lt Eye
 ;;^UTILITY(U,$J,358.3,41238,1,4,0)
 ;;=4^E11.3212
